#1
#1 out of 1
health22h ago
‘Like Christmas’: woman’s relief after test finds she can skip chemotherapy
- The Optima trial found some breast cancer patients could safely skip chemotherapy based on a genomic test.
- Five-year cancer-free survival was 93.7% for those who skipped chemo, versus 94.9% with chemotherapy.
- Karen Bonham from Wales participated and avoided chemotherapy after the test results in 2017.
- The Prosigna test analyzes 50 genes to determine molecular subtype and recurrence risk.
- Experts hail the findings as game-changing for personalizing breast cancer care.
- Results were presented at the American Society of Clinical Oncology meeting in Chicago.
- Bonham reports nine years post-diagnosis with no signs of disease.
- The trial recruited 4,429 patients across multiple countries, including the UK, Norway, and Sweden.
- Some patients still need chemotherapy; decisions depend on individual risk.
Vote 0